JP5584618B2 - 慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用 - Google Patents

慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用 Download PDF

Info

Publication number
JP5584618B2
JP5584618B2 JP2010516366A JP2010516366A JP5584618B2 JP 5584618 B2 JP5584618 B2 JP 5584618B2 JP 2010516366 A JP2010516366 A JP 2010516366A JP 2010516366 A JP2010516366 A JP 2010516366A JP 5584618 B2 JP5584618 B2 JP 5584618B2
Authority
JP
Japan
Prior art keywords
granulin
treatment
therapeutic agent
progranulin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010516366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533660A5 (https=
JP2010533660A (ja
Inventor
テジダー，イルムガルト
ゲイスリンジャー，ゲルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe Universitaet Frankfurt am Main
Original Assignee
Goethe Universitaet Frankfurt am Main
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe Universitaet Frankfurt am Main filed Critical Goethe Universitaet Frankfurt am Main
Publication of JP2010533660A publication Critical patent/JP2010533660A/ja
Publication of JP2010533660A5 publication Critical patent/JP2010533660A5/ja
Application granted granted Critical
Publication of JP5584618B2 publication Critical patent/JP5584618B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010516366A 2007-07-16 2008-07-14 慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用 Expired - Fee Related JP5584618B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007033359.7 2007-07-16
DE102007033359A DE102007033359B4 (de) 2007-07-16 2007-07-16 Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
PCT/DE2008/001138 WO2009010045A1 (de) 2007-07-16 2008-07-14 Verwendung eines granulins oder einer granulin-ähnlichen verbindung zur therapie oder prophylaxe von chronischen schmerzen

Publications (3)

Publication Number Publication Date
JP2010533660A JP2010533660A (ja) 2010-10-28
JP2010533660A5 JP2010533660A5 (https=) 2012-07-05
JP5584618B2 true JP5584618B2 (ja) 2014-09-03

Family

ID=40014940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516366A Expired - Fee Related JP5584618B2 (ja) 2007-07-16 2008-07-14 慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用

Country Status (6)

Country Link
US (2) US8367616B2 (https=)
EP (1) EP2178553B1 (https=)
JP (1) JP5584618B2 (https=)
CA (1) CA2693141C (https=)
DE (1) DE102007033359B4 (https=)
WO (1) WO2009010045A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
CN107349209A (zh) 2008-10-31 2017-11-17 神经机能生命科学公司 神经毒性甾醇糖苷
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
US20210284701A1 (en) * 2016-07-14 2021-09-16 Emory University Granulin Compositions and Uses Related Thereto
CA3165846A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1325792A (en) * 1992-02-03 1993-09-01 Samuel Solomon Granulins from leukocytes
JP2002335972A (ja) * 2000-06-07 2002-11-26 Ajinomoto Co Inc インスリン受容体関連受容体結合蛋白質及びその利用
US6872703B2 (en) * 2000-06-07 2005-03-29 Ajinomoto Co., Inc. Insulin receptor-related receptor binding protein
DE60334499D1 (de) * 2003-02-26 2010-11-18 A & G Pharmaceuticals Inc Verfahren zur erhöhung der ausbreitung von b-zellen
WO2005020902A2 (en) * 2003-08-21 2005-03-10 Cytokine Pharmasciences, Inc. Compositions and methods for treating and diagnosing irritable bowel syndrome
JP4222614B2 (ja) * 2005-02-10 2009-02-12 独立行政法人科学技術振興機構 神経因性疼痛治療剤
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
CA2653974A1 (en) * 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia

Also Published As

Publication number Publication date
WO2009010045A1 (de) 2009-01-22
US9655947B2 (en) 2017-05-23
EP2178553B1 (de) 2013-11-27
CA2693141A1 (en) 2009-01-22
US20130102656A1 (en) 2013-04-25
US20100261657A1 (en) 2010-10-14
DE102007033359A1 (de) 2009-01-29
CA2693141C (en) 2018-01-23
DE102007033359B4 (de) 2010-12-02
EP2178553A1 (de) 2010-04-28
US8367616B2 (en) 2013-02-05
JP2010533660A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
Zhang et al. WNT signaling underlies the pathogenesis of neuropathic pain in rodents
Borkham-Kamphorst et al. Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis
Yu et al. SOCS 3 and PPAR-γ ligands inhibit the expression of IL-6 and TGF-β1 by regulating JAK2/STAT3 signaling in pancreas
US20170258772A1 (en) Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function
JP5584618B2 (ja) 慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用
US20070135340A1 (en) IGF-1 novel peptides
TW201729833A (zh) 用於治療澱粉樣沈著症之方法及組合物
CA3065816C (en) TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF MUSCLE PROTEIN-ANCHORING PROTEINS KINASES A (MAKAP)
Wang et al. Transcriptome analysis provides insight into the anti-diabetic mechanism of theaflavins in high-fat diet and streptozotocin-induced mice
US20090298771A1 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
CN115006534A (zh) 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物
CN112353940A (zh) 一种用于预防或治疗抑郁症的药物及其应用
KR101974504B1 (ko) 호산구성 비용종 동물모델
JPWO2019146805A1 (ja) 前頭側頭葉変性症治療剤、前頭側頭葉変性症治療剤のスクリーニング方法、及び前頭側頭葉変性症の治療方法
US20210290595A1 (en) Gfi1 inhibitors for the treatment of hyperglycemia
TWI843115B (zh) Tnip1蛋白質在抗憂鬱上的用途
US20190381135A1 (en) Compositions and Methods for Spinal Cord Regeneration
Elbaz-Hayoun et al. CCR1 Signaling as a Common Injury Pathway in Retinal Degeneration
JP2007512835A (ja) 新脈管形成に影響を与えるポリペプチド、タンパク質及び組成物、及びそれを使用する方法
Yee Determining the Role of Sost and Sostdc1 During Fracture Healing
EP2135618A2 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
Noesgaard HDAC inhibition as a novel treatment for diabetes mellitus.
Capoccia Quality and chronicity of stressors differentially affect psychoneuroendocrine and immune system cross-talk in mouse models
Glaros Molecular Mechanisms Governing Persistent Induction of Pro-Inflammatory Genes by Lipopolysaccharide
Yoshikawa et al. Missouri-Kansas City, USA, 6Texas A&M Health Science Center, USA, 7Metabolic Disease Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institute of Health, USA, 8National Institute of Diabetes & Digestive & Kidney Diseases, USA, 9Beth Israel Deaconess Medical Center, USA, 10Massachusetts General Hospital, USA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140718

R150 Certificate of patent or registration of utility model

Ref document number: 5584618

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees